BCL2 and diffuse large B-cell lymphoma: In Gill study, no prognostic significance of MYC and/or BCL-2 expression was found in survival.[22] In contrast, Guo et al found that MYC expression alone and MYC/BCL-2 co-expression was significantly associated with poor outcome in patients with PCNS-DLBCL.[34] Kim et al summarized that patients with MYC/BCL-2 co-expression exhibited worse progression-free survival (PFS) in the MTX-treated group, and the same conclusion was got in Shi study.[25,23] Similarly, our research found that patients with c-MYC/BCL2 co-expression trended towards a poor prognosis.